Akebia Therapeutics logo

Akebia Therapeutics Share Price Today

(NASDAQ: AKBA)

Akebia Therapeutics share price is $1.86 & ₹161.76 as on 6 Mar 2025, 2.30 'hrs' IST

$1.86

0.05

(3.06%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Akebia Therapeutics share price in Dollar and Rupees. Guide to invest in Akebia Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Akebia Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Akebia Therapeutics share price movements

  • Today's Low: $1.81
    Today's High: $1.86

    Day's Volatility :2.69%

  • 52 Weeks Low: $0.80
    52 Weeks High: $2.48

    52 Weeks Volatility :67.74%

Akebia Therapeutics (AKBA) Returns

PeriodAkebia Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-10.89%
2.1%
0.0%
6 Months
30.43%
-4.1%
0.0%
1 Year
20.81%
2.2%
0.0%
3 Years
-28.85%
11.8%
-11.6%

Akebia Therapeutics (AKBA) Key Statistics

in dollars & INR

Previous Close
$1.8
Open
$1.82
Today's High
$1.86
Today's Low
$1.81
Market Capitalization
$392.7M
Today's Volume
$320.2K
52 Week High
$2.48
52 Week Low
$0.8
Revenue TTM
$169.9M
EBITDA
$4.4M
Earnings Per Share (EPS)
$-0.22
Profit Margin
-27.07%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-553.45%

How to invest in Akebia Therapeutics Stock (AKBA) from India?

It is very easy for Indian residents to invest directly in Akebia Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Akebia Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Akebia Therapeutics or AKBA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Akebia Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Akebia Therapeutics shares which would translate to 0.468 fractional shares of Akebia Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Akebia Therapeutics, in just a few clicks!

Returns in Akebia Therapeutics (AKBA) for Indian investors in Rupees

The Akebia Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Akebia Therapeutics investment value today

Current value as on today

₹1,29,795

Returns

₹29,795

(+29.79%)

Returns from Akebia Therapeutics Stock

₹24,832 (+24.83%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards Akebia Therapeutics (AKBA)

-51%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Akebia Therapeutics Stock from India on INDmoney has decreased by -51% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Akebia Therapeutics

  • BlackRock Inc

    6.92%

  • Vanguard Group Inc

    4.99%

  • State Street Corp

    2.89%

  • SATTER MANAGEMENT CO., L.P.

    2.63%

  • Geode Capital Management, LLC

    2.20%

  • Renaissance Technologies Corp

    1.75%

Analyst Recommendation on Akebia Therapeutics

Buy

    88%Buy

    11%Hold

    0%Sell

Based on 9 Wall street analysts offering stock ratings for Akebia Therapeutics(by analysts ranked 0 to 5 stars)

Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Akebia Therapeutics Stock (AKBA)

What analysts predicted

Upside of 285.31%

Target:

$7.17

Current:

$1.86

Insights on Akebia Therapeutics Stock (Ticker Symbol: AKBA)

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 43.64M → 37.42M (in $), with an average decrease of 14.3% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -8.58M → -20.03M (in $), with an average decrease of 133.5% per quarter
  • AKBA vs ITCI (1 yr)

    In the last 1 year, Intra-cellular Therapies, Inc. has given 97.0% return, outperforming this stock by 84.5%
  • AKBA vs ITCI (3 yr)

    In the last 3 years, Intra-cellular Therapies, Inc. has given 138.2% return, outperforming this stock by 163.8%
  • Price to Sales

    ForAKBA every $1 of sales, investors are willing to pay $2.2, whereas for Intra-cellular Therapies, Inc., the investors are paying $19.9 for every $1 of sales.

Akebia Therapeutics Technicals Summary

Sell

Neutral

Buy

Akebia Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Akebia Therapeutics (AKBA) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Akebia Therapeutics Inc logo
-15.09%
30.43%
20.81%
-28.85%
-77.64%
Intra-cellular Therapies, Inc. logo
3.42%
81.22%
98.76%
146.55%
588.92%
Haleon Plc Spon Ads logo
12.55%
3.39%
28.09%
43.99%
43.99%
Zoetis Inc. logo
-1.19%
-8.94%
-7.43%
-9.67%
30.97%
Neurocrine Biosciences Inc. logo
-24.64%
-6.68%
-14.47%
28.61%
27.88%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Akebia Therapeutics Inc logo
NA
NA
0.0
-0.26
-5.53
-0.09
NA
-0.24
Intra-cellular Therapies, Inc. logo
NA
NA
0.0
0.13
-0.09
-0.07
NA
10.81
Haleon Plc Spon Ads logo
26.68
26.68
1.5
0.36
0.09
0.04
0.02
1.8
Zoetis Inc. logo
31.17
31.17
3.01
6.07
0.51
0.15
0.01
10.64
Neurocrine Biosciences Inc. logo
34.8
34.8
0.27
6.47
0.14
0.1
NA
26.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Akebia Therapeutics Inc logo
Buy
$392.7M
-77.64%
NA
-27.07%
Intra-cellular Therapies, Inc. logo
Buy
$14.0B
588.92%
NA
-10.97%
Haleon Plc Spon Ads logo
Buy
$48.2B
43.99%
26.68
12.84%
Zoetis Inc. logo
Buy
$76.1B
30.97%
31.17
26.86%
Neurocrine Biosciences Inc. logo
Buy
$11.3B
27.88%
34.8
14.49%

About Akebia Therapeutics

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Organization
Akebia Therapeutics
Employees
167
CEO
Mr. John P. Butler MBA
Industry
Health Technology

Management People of Akebia Therapeutics

NameTitle
Mr. John P. Butler MBA
CEO, President & Director
Dr. Steven Keith Burke M.D.
Senior VP of Research & Development and Chief Medical Officer
Mr. Erik John Ostrowski M.B.A.
Senior VP, CFO & Chief Business Officer
Mr. Richard C. Malabre
Chief Accounting Officer
Ms. Kimberly Garko
Senior VP & Chief Technical Officer
Ms. Tracey Vetterick
Vice President of Portfolio Strategy & Corporate Administration
Mercedes Carrasco
Senior Director of Investor & Corporate Communications
Ms. Carolyn Rucci
Senior VP of Legal, General Counsel & Secretary
Ms. Meredith Bowman
Senior VP & Chief People Officer
Mr. Nicholas Grund
Senior VP & Chief Commercial Officer

Important FAQs about investing in AKBA Stock from India :

What is Akebia Therapeutics share price today?

Akebia Therapeutics share price today stands at $1.86, Open: $1.82 ; Previous Close: $1.80 ; High: $1.86 ; Low: $1.81 ; 52 Week High: $2.48 ; 52 Week Low: $0.80.

The stock opens at $1.82, after a previous close of $1.80. The stock reached a daily high of $1.86 and a low of $1.81, with a 52-week high of $2.48 and a 52-week low of $0.80.

Can Indians buy Akebia Therapeutics shares?

Yes, Indians can invest in the Akebia Therapeutics (AKBA) from India.

With INDmoney, you can buy Akebia Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Akebia Therapeutics at zero transaction cost.

How can I buy Akebia Therapeutics shares from India?

It is very easy to buy Akebia Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Akebia Therapeutics (AKBA) be purchased?

Yes, you can buy fractional shares of Akebia Therapeutics with INDmoney app.

What are the documents required to start investing in Akebia Therapeutics stocks?

To start investing in Akebia Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Akebia Therapeutics Stock (AKBA)?

Today’s highest price of Akebia Therapeutics (AKBA) is $1.86.

Today’s lowest price of Akebia Therapeutics (AKBA) is $1.81.

What is today's market capitalisation of Akebia Therapeutics?

Today's market capitalisation of Akebia Therapeutics AKBA is 392.7M

What is the 52 Week High and Low Range of Akebia Therapeutics Stock (AKBA)?

  • 52 Week High

    $2.48

  • 52 Week Low

    $0.80

What are the historical returns of Akebia Therapeutics (AKBA)?

  • 1 Month Returns

    -15.09%

  • 3 Months Returns

    30.43%

  • 1 Year Returns

    20.81%

  • 5 Years Returns

    -77.64%

Who is the Chief Executive Officer (CEO) of Akebia Therapeutics ?

Mr. John P. Butler MBA is the current Chief Executive Officer (CEO) of Akebia Therapeutics.